What is the potential payout range for the Core Laboratories (CLB) performance share grant?

The award can pay out between 100% and 200% of the initial 7,526 performance share units. A 100% payout occurs at the 55th percentile of ROIC versus peers, while a 200% payout requires performance at or above the 85th percentile benchmark.

Is the Core Laboratories (CLB) performance share grant to Teo Sow Hang a direct holding?

Yes. The Form 4 identifies the 7,526 performance share units as directly owned. They are derivative securities tied to an equal number of Core Laboratories common shares and are reported as beneficially owned following the February 12, 2026 grant transaction.

Core Laboratories (CLB) grants 7,526 performance share units to CAO Teo Sow Hang

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Core Laboratories Inc. granted Chief Accounting Officer and Treasurer Teo Sow Hang 7,526 performance share units on February 12, 2026 at an exercise price of $0 per unit. These derivative awards relate to an equal number of underlying shares of common stock and are held directly.

The award is structured around a three-year performance period from January 1, 2026 through December 31, 2028 and will vest on December 31, 2028, assuming continued employment or qualifying death or disability. Payout depends on Return on Invested Capital versus the Bloomberg Peer Group: 100% of the target amount vests at the top 55th percentile of ROIC, and up to 200% can vest at or above the 85th percentile, with straight-line interpolation between those points.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Teo Sow Hang

Role CAO & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Performance Shares	7,526	$0.00	$0.00

Holdings After Transaction: Performance Shares — 7,526 shares (Direct)

Footnotes (1)

F1. Assuming the recipient's continued employment (or death or disability while employed) and the satisfaction of certain performances criteria set forth below, this award will vest on December 31, 2028, following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). At the end of the Perofrmance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), and 200% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile of ROIC (equivalent to 100% up to 200% of the award).

FAQ

What insider transaction did Core Laboratories (CLB) report for Teo Sow Hang?

Core Laboratories reported a grant of 7,526 performance share units to CAO and Treasurer Teo Sow Hang. The award was made on February 12, 2026 at an exercise price of $0 per unit and is settled in an equal number of common shares.

How many Core Laboratories (CLB) performance shares were granted and at what price?

Teo Sow Hang received 7,526 performance share units of Core Laboratories at an exercise price of $0 per unit. Each unit relates to one share of common stock, and all 7,526 derivative securities are reported as beneficially owned directly after the transaction.

When do Teo Sow Hang’s Core Laboratories (CLB) performance shares vest?

The performance share award is scheduled to vest on December 31, 2028. Vesting occurs after a three-year performance period from January 1, 2026 through December 31, 2028, assuming continued employment or qualifying death or disability and satisfaction of specified performance conditions.

What performance metric determines vesting of the Core Laboratories (CLB) award?

Vesting is tied to Core Laboratories’ Return on Invested Capital versus the Bloomberg Peer Group. At the top 55th percentile of ROIC, 100% of the award vests, and at or above the 85th percentile, 200% can vest, with straight-line interpolation between those points.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/17/2026 - 11:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teo Sow Hang

(Last)

(First)

(Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON

77040

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CAO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Shares	$0	02/12/2026		A		7,526		⁽¹⁾	⁽¹⁾	Common Stock	7,526	$0	7,526	D

Explanation of Responses:

1. Assuming the recipient's continued employment (or death or disability while employed) and the satisfaction of certain performances criteria set forth below, this award will vest on December 31, 2028, following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). At the end of the Perofrmance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), and 200% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile of ROIC (equivalent to 100% up to 200% of the award).

	/s/ Mark Tattoli, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR